SII ships its first set of R21/Matrix-M Malaria Vaccine doses to Africa
The initial shipment will be sent to the Central African Republic (CAR), followed by other African countries such as South Sudan…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Oxford University
Phase 3 trial data confirm efficacy and safety profile of R21/Matrix-M malaria vaccine in African…
Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78 per…
SII manufactures and ships ebola vaccine to Uganda
The bivalent vaccine is designed to target both major strains of ebola virus
British scientists behind key COVID trial launch study to test monkeypox treatment
Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are…
AstraZeneca says its COVID shot has market potential despite lower demand
AstraZeneca has started earning a modest profit on the vaccine, which was initially sold at-cost. However, the British drugmaker…
US scientists develop Nipah virus vaccine that can save lives in just three days
The results, published in the journal Proceedings of the National Academy of Sciences (PNAS), showed all vaccinated monkeys were…
GSK and Oxford University announce Oxford-GSK Institute of Molecular and Computational Medicine
The institute aims to improve the success and speed of research and development of new medicines, building on insights from human…
ICMR proposes clinical trial along with Oxford University to evaluate COVID-19 therapy
The trial -- 'India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy)'-- will be a multi-centre, adaptive platform trial on…
Biotech start-up Vaccitech files for US IPO
Vaccitech owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca
AstraZeneca says COVID-19 vaccine 76 per cent effective in new analysis, to seek US approval
AstraZeneca said its COVID-19 vaccine was 76 per cent effective in a new analysis of its US trial - only a tad lower than the…